Learning Objectives:

1.    Discuss treatment options and decision making for metastatic castrate resistant prostate cancer (mCRPC) that has progressed through multiple lines of therapy
2.    Explore radiotherapies such as Lutetium 177, its role in mCPRC, and identify appropriate patients for therapy
3.    Discuss clinical signs or biomarkers that can predict response to Lutetium 177 and radiotherapeutics

Session date: 
06/27/2024 - 8:00am to 9:00am CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Sarah Poland, MD